Siemens Healthineers (XTRA:SHL) Lifted Guidance On Third Quarter Results, Is The Discount Still There?
Third quarter earnings and guidance shift put Siemens Healthineers in focus
Siemens Healthineers (XTRA:SHL) is back on investors’ radar after third quarter results, a guidance tweak linked to tariff refunds, and fresh value partnerships in the United States.
The company reported third quarter sales of €5,764 million and net income of €669 million, with basic earnings per share from continuing operations of €0.60. Imaging and Precision Therapy segments were highlighted alongside ongoing weakness in Diagnostics.
For the first nine months to June 30, 2026, Siemens Healthineers reported sales of €16,846 million and net income of €1,625 million. Basic earnings per share from continuing operations stood at €1.45 as the company also raised its adjusted earnings per share guidance, citing tariff refunds.
See our latest analysis for Siemens Healthineers.
The latest third quarter update, including higher adjusted earnings guidance tied to tariff refunds and new U.S. value partnerships, comes as Siemens Healthineers trades at €37.2 with a 7 day share price return of 9.32% yet a 1 year total shareholder return that declined 19.46%. This hints at improving short term momentum after a tougher period for longer term holders.
If this earnings story has you thinking about where else capital might find opportunities in healthcare technology, it could be worth scanning other potential healthcare AI leaders through our dedicated screener 128 healthcare AI stocks
For Siemens Healthineers, the recent rebound reflects a balance between firmer earnings guidance and tariff refunds on one side, and a shift in sentiment after a weak year on the other. How does that balance feed into today’s valuation?
Most Popular Narrative: 18.5% Undervalued
On the most widely followed narrative, Siemens Healthineers screens as undervalued, with a fair value of €45.65 compared with the current share price of €37.20. That view rests on a long run earnings and margin story that goes well beyond the latest quarter.
Strong, ongoing innovation in advanced imaging (e.g., Photon Counting CT, molecular imaging) and AI-driven diagnostic solutions is fueling robust order growth across all global markets, supporting both revenue expansion and higher net margins as adoption increases.
Want to see what sits behind that margin uplift story? The narrative leans heavily on steady revenue compounding, firmer profitability and a richer earnings multiple. Curious which assumptions really move that fair value.
Result: Fair Value of €45.65 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors in Siemens Healthineers still need to watch for prolonged pricing pressure in China and ongoing Diagnostics restructuring, which could challenge the higher margin narrative.
Find out about the key risks to this Siemens Healthineers narrative.
Next Steps
Given the mix of optimism around Siemens Healthineers and the caution on risks, it makes sense to review the full picture now and decide where you stand based on the 5 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Siemens Healthineers?
If you want to keep sharpening your edge, do not stop at Siemens Healthineers. Broader idea generation can help you spot opportunities you might otherwise miss.
- Spot potential mispricings by scanning a focused set of quality stocks that currently look cheap on fundamentals through the 259 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies that combine higher yields with resilience using the 433 dividend fortresses.
- Sleep easier at night by checking companies that score well on stability and risk using the 308 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com